Shares of Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) have soared in recent months, fueled by skyrocketing demand for the companies’ respective weight-loss/diabetes drugs tirzepatide, also known ...

South Africa's Competition Commission is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority said on Tuesday, 4 ...

Novo Nordisk, Sanofi face SA insulin antitrust probe The Competition Commission said it has started a probe and is talking to the local units of both drugmakers. By Janice Kew and Naomi Kresge ...

Novo said the amount that Aspen would produce next year under the contract equates to the yearly consumption of 1.1 million people with type 1 and type 2 diabetes.

The Insulin pens are super cheap to manufacture at $1.30. The differential pricing is hard to fathom though – $2.98 in SA (I assume outside of the public sector), $7.88 India and $28.40 in the USA.

This comes after on Tuesday, the companies announced that Aspen Pharmacare had been contracted by the global manufacturer of human insulin, Novo Nordisk, to produce 16 million vials of insulin ...